Compare Enact Holdings Inc (ACT) vs ARK Genomic Revolution ETF (ARKG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Enact Holdings Inc vs ARK Genomic Revolution ETF — how do they compare? Enact Holdings Inc trades at $45.21 (market cap $6.35B), while ARK Genomic Revolution ETF trades at $41.13. The key difference: Enact Holdings Inc pays a 1.91% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ACT | ARKG | |
|---|---|---|
Market Cap | $6.35B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $45.71 | $43.57 |
52-Week Low | $34.39 | $23.09 |
Enterprise Value | $6.55B | — |
Dividend Yield | 1.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $45.69, up 0.77% today, with a bullish technical signal and strong moving averages. The stock shows robust fundamentals with a net income margin of 54.49% and a P/E ratio of 9.89. Recent news includes a 14% dividend increase announced on May 5, 2026, and Q1 2026 earnings that met expectations. Analyst consensus is a $47.50 price target with a mix of buy and hold ratings.
Outlook remains positive due to high profitability and dividend growth, but risks include earnings volatility and market sensitivity. Upside is supported by institutional sentiment and consistent cash flow, though investors should monitor execution against future earnings estimates.
ARKG trades at $43.57, up 1.54% today, with strong technical momentum as moving averages signal bullish sentiment. The ETF benefits from positive biotech sector trends including FDA friendliness and M&A activity. However, key oscillators show neutral readings with RSI indicators suggesting overbought conditions near the $45 resistance level.
The biotech ETF outlook remains favorable amid sector strength, though elevated RSI levels indicate potential near-term consolidation. Investment opportunity lies in continued sector momentum, while risks include market volatility and selective investor sentiment toward biotech companies as noted by JPMorgan bankers in June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →
